問卷

TPIDB > Search Result

Search Result

篩選

List

13Cases

2025-06-01 - 2028-05-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2020-01-31 - 2023-10-03

Phase II/III

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Condition/Disease

    PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    GSK3359609

Participate Sites
7Sites

Recruiting7Sites

1 2